West Nile Vaccine
Intervet Inc. licensed the exclusive rights to a new veterinary West Nile virus vaccine technology from Acambis, a company with expertise in discovering, developing and manufacturing human vaccines to prevent and treat infectious diseases.
Intervet Inc. licensed the exclusive rights to a new veterinary West Nile virus vaccine technology from Acambis, a company with expertise in discovering, developing and manufacturing human vaccines to prevent and treat infectious diseases.
Acambis is developing an investigational human vaccine against West Nile virus (WNV) using proprietary chimeric vaccine technology called ChimeriVax™. Intervet is exploring how this technology can be applied to the development of an equine WNV vaccine.
The Acambis technology was first developed for human vaccines, where the 17D vaccine strain of human yellow fever (YF) is modified to mimic WNV, creating a chimeric vaccine — a process that uses the YF virus to serve as a backbone into which certain elements of the target virus are inserted, the company explains.
For fastest response, call
(800) 441-8272
